PMID- 34428860
OWN - NLM
STAT- MEDLINE
DCOM- 20220426
LR  - 20220426
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Linking)
VI  - 88
IP  - 3
DP  - 2022 Mar
TI  - Efficacy and safety of roxadustat for anaemia in dialysis-dependent and 
      non-dialysis-dependent chronic kidney disease patients: A systematic review and 
      meta-analysis.
PG  - 919-932
LID - 10.1111/bcp.15055 [doi]
AB  - AIMS: Renal anaemia is a common complication of chronic kidney disease (CKD). 
      Roxadustat is the first-in-class oral hypoxia-inducible factor prolyl hydroxylase 
      inhibitor for the treatment of anaemia. In this systematic review, we aimed to 
      investigate the efficacy and safety of roxadustat in the treatment of anaemia in 
      CKD patients. METHODS: PubMed, Cochrane Library, Embase, and ClinicalTrials.gov 
      databases were searched from their inception to February 2021 for randomised 
      controlled trials (RCTs) that compared the efficacy and safety of roxadustat to 
      those of an erythropoiesis-stimulating agent (ESA) or a placebo in treating 
      anaemia in CKD patients. RESULTS: Nine RCTs involving 2743 patients were found. 
      The meta-analysis showed that roxadustat increased haemoglobin (Hb) level by 
      0.91 g/dL (95% confidence interval [CI]: 0.47-1.34, P < .05), transferrin level 
      by 0.50 mg/dL (95% CI: 0.34-0.65, P < .05), and total iron-binding capacity by 
      50.64 mug/dL (95% CI: 36.21-65.07, P < .05) in CKD patients. Decreases in hepcidin 
      (mean difference [MD] = -23.16, 95% CI: -37.12 to -9.19, P < .05) and ferritin 
      (MD = -38.35, 95% CI: -67.41 to -9.29, P < .05) levels were also observed. There 
      was no significant difference in the incidence of adverse events (AEs) (OR: 1.12, 
      95% CI: 0.95-1.32, P = .17) between the roxadustat and control groups; however, 
      the incidence of serious AEs in the roxadustat group was significantly higher 
      than that in the ESA group (OR: 1.33, 95% CI: 1.06-1.68, P < .05). CONCLUSION: 
      Roxadustat can significantly improve renal anaemia in CKD patients by increasing 
      Hb level and iron metabolism. However, attention must be paid to the risk of SAEs 
      during treatment.
CI  - (c) 2021 British Pharmacological Society.
FAU - Zheng, Li
AU  - Zheng L
AUID- ORCID: 0000-0003-0971-0343
AD  - Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou 
      University, Lanzhou, China.
AD  - Department of Pharmacy, China Aerospace Science & Industry Corporation 731 
      Hospital, Beijing, China.
FAU - Tian, Jinhui
AU  - Tian J
AUID- ORCID: 0000-0002-0054-2454
AD  - Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou 
      University, Lanzhou, China.
FAU - Liu, Deping
AU  - Liu D
AUID- ORCID: 0000-0001-5887-4120
AD  - Department of Cardiovascular Medicine, Beijing Hospital, National Center of 
      Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical 
      Sciences, Beijing, China.
FAU - Zhao, Yan
AU  - Zhao Y
AD  - Department of Pharmacy, China Aerospace Science & Industry Corporation 731 
      Hospital, Beijing, China.
FAU - Fang, Xiaoyong
AU  - Fang X
AD  - Department of Pharmacy, China Aerospace Science & Industry Corporation 731 
      Hospital, Beijing, China.
FAU - Zhang, Yatong
AU  - Zhang Y
AD  - Department of Pharmacy, Beijing Hospital, Beijing, China.
FAU - Liu, Yuming
AU  - Liu Y
AD  - Department of Endocrinology and Metabolism and Nephropathy, China Aerospace 
      Science & Industry Corporation 731 Hospital, Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
DEP - 20210930
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 0 (Hematinics)
RN  - 0 (Isoquinolines)
RN  - E1UOL152H7 (Iron)
RN  - TE7660XO1C (Glycine)
RN  - X3O30D9YMX (roxadustat)
SB  - IM
MH  - *Anemia/drug therapy/etiology
MH  - Female
MH  - Glycine/analogs & derivatives
MH  - *Hematinics/adverse effects
MH  - Humans
MH  - Iron
MH  - Isoquinolines
MH  - Male
MH  - Renal Dialysis/adverse effects
MH  - *Renal Insufficiency, Chronic/drug therapy/therapy
OTO - NOTNLM
OT  - chronic kidney disease
OT  - meta-analysis
OT  - renal anaemia
OT  - roxadustat
EDAT- 2021/08/25 06:00
MHDA- 2022/04/27 06:00
CRDT- 2021/08/24 20:29
PHST- 2021/08/08 00:00 [revised]
PHST- 2021/04/15 00:00 [received]
PHST- 2021/08/12 00:00 [accepted]
PHST- 2021/08/25 06:00 [pubmed]
PHST- 2022/04/27 06:00 [medline]
PHST- 2021/08/24 20:29 [entrez]
AID - 10.1111/bcp.15055 [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 2022 Mar;88(3):919-932. doi: 10.1111/bcp.15055. Epub 2021 
      Sep 30.